These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 12734781

  • 21. Impact of diabetes duration on hypoglycaemia in patients with type 2 diabetes treated with insulin glargine or NPH insulin.
    Dailey GE, Gao L, Aurand L, Garg SK.
    Diabetes Obes Metab; 2013 Dec; 15(12):1085-92. PubMed ID: 23683002
    [Abstract] [Full Text] [Related]

  • 22. Comparison of safety and efficacy of insulin glargine and neutral protamine hagedorn insulin in older adults with type 2 diabetes mellitus: results from a pooled analysis.
    Lee P, Chang A, Blaum C, Vlajnic A, Gao L, Halter J.
    J Am Geriatr Soc; 2012 Jan; 60(1):51-9. PubMed ID: 22239291
    [Abstract] [Full Text] [Related]

  • 23. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride.
    Eliaschewitz FG, Calvo C, Valbuena H, Ruiz M, Aschner P, Villena J, Ramirez LA, Jimenez J, HOE 901/4013 LA Study Group.
    Arch Med Res; 2006 May; 37(4):495-501. PubMed ID: 16715577
    [Abstract] [Full Text] [Related]

  • 24. Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus.
    Rys P, Wojciechowski P, Rogoz-Sitek A, Niesyczyński G, Lis J, Syta A, Malecki MT.
    Acta Diabetol; 2015 Aug; 52(4):649-62. PubMed ID: 25585592
    [Abstract] [Full Text] [Related]

  • 25. A comparison of bedtime insulin glargine with bedtime neutral protamine hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study.
    Fonseca V, Bell DS, Berger S, Thomson S, Mecca TE.
    Am J Med Sci; 2004 Nov; 328(5):274-80. PubMed ID: 15545844
    [Abstract] [Full Text] [Related]

  • 26. Impact of patient and treatment characteristics on glycemic control and hypoglycemia in patients with type 2 diabetes initiated to insulin glargine or NPH: A post hoc, pooled, patient-level analysis of 6 randomized controlled trials.
    Porcellati F, Lin J, Lucidi P, Bolli GB, Fanelli CG.
    Medicine (Baltimore); 2017 Feb; 96(5):e6022. PubMed ID: 28151905
    [Abstract] [Full Text] [Related]

  • 27. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.
    Raskin P, Klaff L, Bergenstal R, Hallé JP, Donley D, Mecca T.
    Diabetes Care; 2000 Nov; 23(11):1666-71. PubMed ID: 11092290
    [Abstract] [Full Text] [Related]

  • 28. Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial.
    Rosenstock J, Fonseca V, Schinzel S, Dain MP, Mullins P, Riddle M.
    J Diabetes Complications; 2014 Nov; 28(5):742-9. PubMed ID: 24856612
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study.
    Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Lüddeke HJ.
    Diabetes Obes Metab; 2007 May; 9(3):418-27. PubMed ID: 17391170
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Glargine versus NPH insulin: efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes--the glargine and aspart study (GLASS) a randomised cross-over study.
    Chatterjee S, Jarvis-Kay J, Rengarajan T, Lawrence IG, McNally PG, Davies MJ.
    Diabetes Res Clin Pract; 2007 Aug; 77(2):215-22. PubMed ID: 17141354
    [Abstract] [Full Text] [Related]

  • 35. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes.
    Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A.
    Diabetes Care; 2005 Apr; 28(4):950-5. PubMed ID: 15793205
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE.
    Dornhorst A, Lüddeke HJ, Koenen C, Meriläinen M, King A, Robinson A, Sreenan S, PREDICTIVE Study Group.
    Diabetes Obes Metab; 2008 Jan; 10(1):75-81. PubMed ID: 18034846
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.